F-star 
Welcome,         Profile    Billing    Logout  
 6 Products   0 Diseases  6 Products   4 Trials   216 News 
5 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FS118 / Sino Biopharm
2021-003406-47: FS118 Phase 2 Study in Patients with Advanced Malignancies

Not yet recruiting
2
94
Europe
FS118, Solution for infusion
invoX Pharma Limited, invoX Pharma Limited
Advanced and early-stage malignancies, Severe malignancies, Diseases [C] - Cancer [C04]
 
 
NCT03440437: A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

Hourglass Apr 2022 - Sep 2022 : From trial for advanced cancer
Checkmark For advanced cancer
Nov 2020 - Nov 2020: For advanced cancer
Terminated
1/2
80
Europe, US
FS118, Paclitaxel
invoX Pharma Limited
Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
06/24
06/24
SB 11285 / Sino Biopharm
NCT04096638: Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Checkmark Data from trial in combination with Tecentriq for solid tumors
Jul 2021 - Jul 2021: Data from trial in combination with Tecentriq for solid tumors
Completed
1
61
US
SB 11285, Atezolizumab, Tecentriq
invoX Pharma Limited
Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
07/24
07/24
FS120 / Sino Biopharm
KEYNOTE-C82, NCT04648202: FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Active, not recruiting
1
82
Europe, US
FS120, Pembrolizumab (KEYTRUDA®)
invoX Pharma Limited, Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
03/26
03/26
FS222 / Sino Biopharm
FS222-19101, NCT04740424: FS222 First in Human Study in Patients With Advanced Malignancies

Recruiting
1
260
Europe, RoW
FS222
invoX Pharma Limited
Advanced Cancer, Metastatic Cancer
10/27
10/27
SB 11736 / AstraZeneca
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FS118 / Sino Biopharm
2021-003406-47: FS118 Phase 2 Study in Patients with Advanced Malignancies

Not yet recruiting
2
94
Europe
FS118, Solution for infusion
invoX Pharma Limited, invoX Pharma Limited
Advanced and early-stage malignancies, Severe malignancies, Diseases [C] - Cancer [C04]
 
 
NCT03440437: A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

Hourglass Apr 2022 - Sep 2022 : From trial for advanced cancer
Checkmark For advanced cancer
Nov 2020 - Nov 2020: For advanced cancer
Terminated
1/2
80
Europe, US
FS118, Paclitaxel
invoX Pharma Limited
Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
06/24
06/24
SB 11285 / Sino Biopharm
NCT04096638: Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Checkmark Data from trial in combination with Tecentriq for solid tumors
Jul 2021 - Jul 2021: Data from trial in combination with Tecentriq for solid tumors
Completed
1
61
US
SB 11285, Atezolizumab, Tecentriq
invoX Pharma Limited
Melanoma, Head and Neck Squamous Cell Carcinoma, Solid Tumor
07/24
07/24
FS120 / Sino Biopharm
KEYNOTE-C82, NCT04648202: FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Active, not recruiting
1
82
Europe, US
FS120, Pembrolizumab (KEYTRUDA®)
invoX Pharma Limited, Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
03/26
03/26
FS222 / Sino Biopharm
FS222-19101, NCT04740424: FS222 First in Human Study in Patients With Advanced Malignancies

Recruiting
1
260
Europe, RoW
FS222
invoX Pharma Limited
Advanced Cancer, Metastatic Cancer
10/27
10/27
SB 11736 / AstraZeneca
No trials found

Download Options